Last Updated : April 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
| TBD | Entrectinib | Withdrawn | ||||
| TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Active | |||
| Olumiant | baricitinib | Alopecia areata, severe | Active | |||
| Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older | Active | |||
| N/A | nab-paclitaxel | Gastrointestinal cancer | Pending | |||
| Alecensaro | alectinib | ALK-positive NSCLC | Pending | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Pending | |||
| TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Pending | |||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended |
Last Updated : April 16, 2024